| scholarly article | Q13442814 |
| review article | Q7318358 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1085378630 |
| P356 | DOI | 10.1186/S12891-017-1543-Z |
| P932 | PMC publication ID | 5427554 |
| P698 | PubMed publication ID | 28499370 |
| P2093 | author name string | Li-Wei Zhang | |
| Pan Wei | |||
| Hong Hua | |||
| Shi-Qin Wang | |||
| P2860 | cites work | Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements | Q26800693 |
| The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations | Q46076311 | ||
| Salivary resistin reflects local inflammation in Sjögren's syndrome | Q46424826 | ||
| B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome | Q50978347 | ||
| Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome. | Q52234497 | ||
| Sjögren's syndrome | Q55921808 | ||
| Sjögren’s syndrome | Q56224755 | ||
| Pathogenesis of Sjögren's syndrome | Q84149203 | ||
| Relation of Systemic Autoantibodies to the Number of Extraglandular Manifestations in Primary Sjögren's Syndrome: A Retrospective Analysis of 65 Patients in the Netherlands | Q85073051 | ||
| Epidemiology of Sjögren's Syndrome-from an Oral Perspective | Q28069816 | ||
| Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation | Q29615706 | ||
| Treatment of primary Sjögren syndrome | Q30249011 | ||
| Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial | Q33565459 | ||
| Antimalarials for rheumatoid arthritis | Q33908151 | ||
| Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. | Q34396739 | ||
| Cytokines in Sjogren's syndrome: potential therapeutic targets | Q34601660 | ||
| Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial | Q34663199 | ||
| Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort | Q34743817 | ||
| Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers | Q35548532 | ||
| Sjögren syndrome: advances in the pathogenesis from animal models | Q36226075 | ||
| Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy | Q36748972 | ||
| An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome | Q36925321 | ||
| Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study | Q36989837 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Treatment of primary Sjögren syndrome: a systematic review | Q37776086 | ||
| Primary Sjogren syndrome. | Q38018910 | ||
| Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis | Q38107925 | ||
| Sjögren's syndrome: where do we stand, and where shall we go? | Q38194705 | ||
| Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis | Q38220995 | ||
| Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting? | Q38245657 | ||
| Rheumatoid arthritis: Perioperative management of biologics and DMARDs | Q38369388 | ||
| Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases | Q38561490 | ||
| Recommendations for the treatment of Sjögren's syndrome | Q38584878 | ||
| Primary Sjӧgren's syndrome: Clinical phenotypes, outcome and the development of biomarkers | Q38771588 | ||
| New Treatment Guidelines for Sjögren's Disease | Q38840388 | ||
| Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain | Q38889818 | ||
| Sjögren's syndrome-associated myositis with germinal centre-like structures | Q39042311 | ||
| The histopathology of Sjögren's syndrome in labial salivary gland biopsies | Q39935383 | ||
| Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome | Q41924912 | ||
| Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. | Q41930645 | ||
| Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine | Q41933097 | ||
| Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study | Q41935495 | ||
| Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome | Q41936291 | ||
| Treatment of primary Sjögren's syndrome with hydroxychloroquine | Q41947036 | ||
| Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. | Q44301752 | ||
| Prevalence of primary Sjögren's syndrome in an elderly population | Q44356526 | ||
| Topical and systemic medications for the treatment of primary Sjögren's syndrome. | Q44498935 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heterocyclic compound | Q193430 |
| Sjögren's syndrome | Q335555 | ||
| systematic review | Q1504425 | ||
| hydroxychloroquine | Q421094 | ||
| disease-modifying antirheumatic drug | Q810254 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 186 | |
| P577 | publication date | 2017-05-12 | |
| P1433 | published in | BMC Musculoskeletal Disorders | Q15751716 |
| P1476 | title | Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis | |
| P478 | volume | 18 |
| Q88873799 | Advances in the diagnosis and treatment of Sjogren's syndrome |
| Q90382919 | Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q40067064 | Cutaneous and Mucosal Manifestations of Sjögren's Syndrome |
| Q92026856 | Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues |
| Q93014004 | Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial |
| Q64094947 | Managing fatigue in patients with primary Sjögren's syndrome: challenges and solutions |
| Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
| Q48341665 | Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy. |
| Q47133516 | Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome |
| Q92617316 | The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis |
| Q90433157 | Ultrasonographic Changes of Major Salivary Glands in Primary Sjögren's Syndrome |
| Q64044871 | [Collagenosis and vasculitis-what is allowed in treatment?] |
Search more.